Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 7.3 %

Shares of NASDAQ EVOK opened at $4.42 on Monday. The company has a market capitalization of $6.57 million, a PE ratio of -0.40 and a beta of 0.16. The firm has a fifty day simple moving average of $4.87 and a 200 day simple moving average of $5.21. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $13.80.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.